ライフサイエンスコーパス: uveal melanoma

1 led for enucleation as primary treatment for uveal melanoma.

2 embers of this kindred reported a history of uveal melanoma.

3 r exploited as a biomarker for monitoring of uveal melanoma.

4 the initiation and metastatic progression of uveal melanoma.

5 esized to play a role in the pathogenesis of uveal melanoma.

6 cificity in the identification of metastatic uveal melanoma.

7 protein 1 gene) are frequently identified in uveal melanoma.

8 edition of the AJCCCancer Staging Manual for uveal melanoma.

9 tient-specific data fields for patients with uveal melanoma.

10 ng the standard of care in the management of uveal melanoma.

11 overall survival in patients with metastatic uveal melanoma.

12 thought to occur early in the development of uveal melanoma.

13 ars to be a prognostic factor for death from uveal melanoma.

14 individual prediction model of survival from uveal melanoma.

15 -year period of 47 consecutive patients with uveal melanoma.

16 ng response to targeted molecular therapy in uveal melanoma.

17 e targeted molecular agents in patients with uveal melanoma.

18 ccination is feasible and safe in metastatic uveal melanoma.

19 n on 5-year risk of death after diagnosis of uveal melanoma.

20 cinoma, mesothelioma and meningioma, but not uveal melanoma.

21 is not recommended as a prognostic marker in uveal melanoma.

22 resolution after brachytherapy of posterior uveal melanoma.

23 relationship between cutaneous vitiligo and uveal melanoma.

24 icrometastasis in the liver of patients with uveal melanoma.

25 arboplatin and paclitaxel (CP) in metastatic uveal melanoma.

26 rome with increased risk of mesothelioma and uveal melanoma.

27 ng Notch activity, growth, and metastasis in uveal melanoma.

28 re not the primary drivers of oncogenesis in uveal melanoma.

29 -type, six BRAF status unknown), and 16 with uveal melanoma.

30 me that is characterized by mesothelioma and uveal melanoma.

31 h mutant BAP1 were previously diagnosed with uveal melanoma.

32 lioma, some BAP1 mutation carriers developed uveal melanoma.

33 ocular neoplasms such as retinoblastoma and uveal melanoma.

34 TILs) could mediate regression of metastatic uveal melanoma.

35 umour regression in patients with metastatic uveal melanoma.

36 RAB31 was a predictor of metastasis risk in uveal melanoma.

37 lps determine the diagnosis and prognosis in uveal melanoma.

38 A total of 1059 patients with uveal melanoma.

39 protein-1 gene (BAP1) predispose carriers to uveal melanoma.

40 ion retinopathy and alternative therapies of uveal melanoma.

41 etected in 2 of 8 families with a history of uveal melanoma.

42 ptomatic metastases in patients with primary uveal melanoma.

43 stemic surveillance in patients with primary uveal melanoma.

44 nti-cMET monoclonal antibodies in metastatic uveal melanoma.

45 nt probe amplification were performed in the uveal melanomas.

46 ations denote a distinct molecular subset of uveal melanomas.

47 compared to sun-shielded acral, mucosal and uveal melanomas.

48 D147 and MMP-2 was analyzed in 49 samples of uveal melanomas.

49 d MMP-2 were expressed in 47 (96.0 %) of the uveal melanomas.

50 tely half of the patients died of metastatic uveal melanoma (10-year rate, 48.5%; 95% CI, 43.0%-54.4%

51 uveal melanoma xenografts, 57 patients with uveal melanoma (17 patients whose tumors metastasized an

52 malacia secondary to plaque radiotherapy for uveal melanoma, 2 patients had suspicious uveoscleral ne

53 Fifty cases of uveal melanoma (28 males, 22 females) treated by enuclea

54 From 732 patients diagnosed with uveal melanoma, 311 were treated with brachytherapy.

55 atients treated with plaque radiotherapy for uveal melanoma, 73 (1%) developed radiotherapy-induced s

56 y period 515 enucleations were performed for uveal melanoma, 99 (19%) of which were secondary enuclea

57 ying YAP as a suitable therapeutic target in uveal melanoma, a GNAQ/GNA11-initiated human malignancy.

58 aluated 48 patients with local recurrence of uveal melanoma after primary treatment with brachytherap

59 s known about the long-term risk of dying of uveal melanoma after treatment with radiotherapy.

60 ent selection criteria included diagnosis of uveal melanoma and adequate records to allow tumor stagi

61 ermline BAP1 mutations occur infrequently in uveal melanoma and are associated with larger tumors and

62 ntervals (95%CIs) with respect to death from uveal melanoma and death from all causes.

63 concepts of the cytogenetic pathogenesis of uveal melanoma and demonstrate the potential problems an

64 t is the most robust prognostic indicator in uveal melanoma and early studies of mostly larger tumors

65 responses were observed in one patient with uveal melanoma and four of 15 evaluable patients with RC

66 issense variants we identified are common in uveal melanoma and have been shown to constitutively act

67 between the BAP1 immunoreactivity of primary uveal melanoma and other clinicopathologic features.

68 t intraocular tumors in adults and children (uveal melanoma and retinoblastoma, respectively).

69 Clinical characteristics of uveal melanoma and the development of metastases.

70 expression with major prognostic factors for uveal melanoma and the development of metastasis.

71 Choroidal nevus is a precursor for uveal melanoma and there are no known risk factors besid

72 alpha subunits, are the driver oncogenes in uveal melanoma, and mutations in Gq-linked G protein-cou

73 eir lifetime, mostly malignant mesothelioma, uveal melanoma, and so on.

74 enase [LDH]) perform poorly in patients with uveal melanoma, and the search for new biomarkers is nee

75 uveal melanoma; iii) metastasizing disomy 3 uveal melanoma; and iv) monosomy 3 uveal melanoma with l

76 cal studies of systemic adjuvant therapy for uveal melanoma are enhanced by multistage trial designs

77 Recent advances in the molecular genetics of uveal melanoma are revolutionizing our understanding of

78 Uveal melanomas are molecularly distinct from cutaneous

79 In Finland, uveal melanomas are treated centrally in the Ocular Onco

80 In this matched study, patients with uveal melanoma associated with COM were twice as likely

81 Patients with uveal melanoma associated with oculo(dermal) melanocytos

82 edictive of metastasis in patients harboring uveal melanoma associated with oculo(dermal) melanocytos

83 mber 2013 among 120 patients with metastatic uveal melanoma at 15 academic oncology centers in the Un

84 Sampling of a clinically diagnosed posterior uveal melanoma at a single site for prognostic GEP testi

85 treated with primary proton beam therapy for uveal melanoma at the oncology service at Charite-Berlin

86 Early detection of posterior uveal melanoma, at a point when the tumor is small, can

87 lopment of a new molecular classification of uveal melanoma based on a widely available 15-gene expre

88 All were referred because of suspected uveal melanoma, based on ultrasonographic imaging.

89 linical macular edema is common in eyes with uveal melanoma before and at 4 months after plaque radio

90 indicated only in case of re-recurrences of uveal melanoma, but not because of secondary complicatio

91 GNAQ and GNA11 are frequently mutated in uveal melanoma, but they remain difficult therapeutic ta

92 Patients with uveal melanoma can develop vitiligo spontaneously or fol

93 Levels of sc-Met in uveal melanoma cell cultures and in the blood serum samp

94 t was studied in the conditioned medium of 9 uveal melanoma cell lines and in the blood serum samples

95 The conditioned medium of uveal melanoma cell lines and the blood serum samples of

96 The TSN from uveal melanoma cell lines is capable of affecting the ch

97 onstructs or downregulated by sh-Jag2 in the uveal melanoma cell lines Mel285, Mel290, 92.1, and OMM1

98 The human uveal melanoma cell lines Mel290 and Mel 270, HUVECs, mo

99 Bves overexpression in uveal melanoma cell lines resulted in increased expressi

100 resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibito

101 were measured using qPCR and Western blot in uveal melanoma cell lines.

102 ARF6 with a small-molecule inhibitor reduces uveal melanoma cell proliferation and tumorigenesis in a

103 ere, in a series of experiments, using human uveal melanoma cells (MEL 270), human embryonic kidney c

104 emonstrated when injection of CXCR4-negative uveal melanoma cells into mice resulted in reduced liver

105 -1ra did not affect the proliferation of the uveal melanoma cells or their production of IL-1, IL-6,

106 Exposure of freshly cultured uveal melanoma cells to hypoxia led to an increased expr

107 Galphaq promotes the YAP-dependent growth of uveal melanoma cells, thereby identifying YAP as a suita

108 differentially expressed in cultured primary uveal melanoma cells.

109 o limit metastatic progression of monosomy 3 uveal melanoma cells.

110 iver metastasis compared with CXCR4-positive uveal melanoma cells.

111 promoting invasion and clonogenic growth of uveal melanoma cells.

112 ate that CD147 regulates MMP-2 expression in uveal melanoma cells.

113 Compared with uveal melanoma classified as AJCC stage I, the rate of m

114 Compared with uveal melanoma classified as T1, the rate of metastasis

115 The TSN of 1 cell line and 2 primary uveal melanoma cultures inhibited the dendritic cell mat

116 From the Wills Eye Hospital Oncology Service Uveal Melanoma Cytogenetic Database (N = 1172), 128 pati

117 shed new light on the molecular genetics of uveal melanoma, delineating it as an atypical tumor of t

118 every 4 months after plaque radiotherapy for uveal melanoma demonstrated OCT-evident macular edema, c

119 approximately 5% of patients with a disomy 3 uveal melanoma develop metastases, and a further 5% of m

120 , whereas somatic Galpha11 mutations mediate uveal melanoma development by constitutively up-regulati

121 efficacy of CP plus sorafenib in metastatic uveal melanoma did not warrant further clinical testing

122 ) in patients undergoing prognostication for uveal melanoma does not exist.

123 ice, of healthy donors, and of patients with uveal melanoma during follow-up.

124 our patients developed nonorbital metastatic uveal melanoma during the study period.

125 high local tumor control rates in recurrent uveal melanoma, especially if the primary therapy was tr

126 ondition that can lead to the development of uveal melanoma, estimated at 1 in 400 affected patients.

127 astatic death in 299 patients with posterior uveal melanoma evaluated by fine-needle aspiration biops

128 Many patients with uveal melanoma experience long delays in treatment becau

129 Patients diagnosed with uveal melanoma from 1995 to 2016 and treated with episcl

130 ent selection criteria included diagnosis of uveal melanoma from April 1, 2001, to April 1, 2011, ade

131 with episcleral brachytherapy for posterior uveal melanoma from January 2004 to December 2014.

132 All patients with a clinical diagnosis of uveal melanoma from May 2009 to July 2013 who underwent

133 on, and assessed the effect of NPS-2143 on a uveal melanoma Galpha11 mutant.

134 ing brachytherapy in patients with posterior uveal melanoma, given that an understanding of the recur

135 scleromalacia secondary to radiotherapy for uveal melanoma, grafts were placed several years after t

136 HF-US is a practical method to track uveal melanoma growth in the same nude rat or SCID mouse

137 One patient without a family history of uveal melanoma had a single nucleotide substitution in t

138 The vast majority of primary large uveal melanomas harbor mutually-exclusive mutations in G

139 date, the role of germline BAP1 mutations in uveal melanoma has not been characterized.

140 The treatment of uveal melanoma has seen a shift towards eye conserving t

141 The techniques for assessing prognosis in uveal melanoma have evolved from simple physical feature

142 Some uveal melanomas have activating mutations in GNAQ and GN

143 r molecular prognostication in patients with uveal melanoma; however, class 1 and class 2 test result

144 te four clinically well-defined subgroups of uveal melanoma: i) disomy 3 uveal melanoma with long-ter

145 his analysis, we included 3088 patients with uveal melanoma, identified from a hospital-based cohort

146 -term survival; ii) metastasizing monosomy 3 uveal melanoma; iii) metastasizing disomy 3 uveal melano

147 se patients from 6 families had a history of uveal melanoma in 1 relative, and 2 patients from 2 addi

148 cause of death was metastatic disease due to uveal melanoma in 561 patients.

149 nhance the host's antitumor immunity against uveal melanoma in approximately one third of patients.

150 Both had a family history of uveal melanoma in at least 1 relative.

151 The number with uveal melanoma in PES studies has been small.

152 ents who underwent secondary enucleation for uveal melanoma in the London Ocular Oncology Service, be

153 The importance of CXCR4 expression by uveal melanomas in metastasis to the liver was recently

154 d, repeatable system for dividing metastatic uveal melanoma into distinct prognostic subgroups, espec

155 A diagnosis of choroidal melanoma (ie, any uveal melanoma involving the choroid).

156 Uveal melanoma is a rare tumour with no established trea

157 Uveal melanoma is a serious life-threatening intraocular

158 Thus, uveal melanoma is among a small group of cancers associa

159 pression of the oncoprotein c-Met in primary uveal melanoma is associated with metastatic progression

160 Uveal melanoma is characterized by mutations in GNAQ and

161 loss following episcleral brachytherapy for uveal melanoma is difficult to predict for individual pa

162 results challenge the belief that metastatic uveal melanoma is immunotherapy resistant and support th

163 Controlling the spread of uveal melanoma is key to improving survival of patients

164 Uveal melanoma is the most common primary cancer of the

165 Uveal melanoma is the most common primary intraocular ma

166 ion regarding the long-term risk of dying of uveal melanoma may be useful to clinicians when counseli

167 Forty patients with uveal melanoma (mean age, 57.98+/-14.75 years) were incl

168 ted protein-1 (BAP1) gene has been linked to uveal melanoma, mesothelioma, meningioma, renal cell car

169 ntial therapeutic agent for the treatment of uveal melanoma micrometastases.

170 MUM2B and the nonaggressive/noninvasive OCM1 uveal melanoma models were examined in vitro and in vivo

171 ERK phosphorylation associated with ADH2 and uveal melanoma mutants was rectified by NPS-2143.

172 lignancies among BAP1 mutation carriers were uveal melanoma (n = 60 [28%]), mesothelioma (n = 48 [22%

173 Patients undergoing enucleation for uveal melanoma need to be informed of the possibility of

174 temic metastasis compared with patients with uveal melanoma not associated with COM.

175 tosis group was matched with 2 patients with uveal melanoma not associated with ocular melanocytosis

176 Metastatic death from uveal melanoma occurs almost exclusively with tumors sho

177 Of 7872 patients with uveal melanoma, oculo(dermal) melanocytosis was present

178 tasis-related mutations in highly metastatic uveal melanomas of the eye.

179 Our findings implicate CYSLTR2 as a uveal melanoma oncogene and highlight the critical role

180 of certain heterotrimeric G proteins, drive uveal melanoma oncogenesis by triggering multiple downst

181 mutually exclusive pattern in most cases of uveal melanoma, one of the most aggressive cancers.

182 n-dependent probe amplification assays (P027 uveal melanoma, P036 human telomere, and P206 spitzoid m

183 ht the critical role of Galphaq signaling in uveal melanoma pathogenesis.

184 A committee was formed to create uveal melanoma patient-specific data fields.

185 oma specific mortality among newly diagnosed uveal melanoma patients after five years.

186 rm outcomes concerning globe preservation in uveal melanoma patients after proton beam therapy with t

187 p metastases, and a further 5% of monosomy 3 uveal melanoma patients exhibit disease-free survival fo

188 in vivo and a subset of liver metastases of uveal melanoma patients express activated forms of ERBB2

189 A total of 197 uveal melanoma patients from a single institution were a

190 atment and long-term surveillance of treated uveal melanoma patients is necessary.

191 Uveal melanoma patients with ischemic retinal detachment

192 Uveal melanoma patients with metastatic disease usually

193 but show only modest efficacy in metastatic uveal melanoma patients.

194 us could be determined in 97.3% (n = 110) of uveal melanoma patients.

195 d survival suggests a biological function in uveal melanoma, possibly working to limit metastatic pro

196 IL-1 may play a role in promoting uveal melanoma progression.

197 ecent discovery of major driver mutations in uveal melanoma provide a rational basis for development

198 ee on Cancer's 7th Edition Classification of Uveal Melanoma," published online January 2, 2015, in JA

199 erapy (EPBT) for locally recurrent posterior uveal melanoma (PUM).

200 Patients with metastatic uveal melanoma received at least 3 vaccinations with aut

201 e 3, 2003, and March 18, 2008, patients with uveal melanoma received SDRT monotherapy (group 1, 60 pa

202 To determine the personalized rate of uveal melanoma-related metastasis on the basis of indivi

203 Of 1059 patients with uveal melanoma sampled for status of chromosomes 3, 6, a

204 We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in

205 of proinflammatory genes in freshly cultured uveal melanoma samples was studied in an in vitro 24-hou

206 s-generating study of patients with advanced uveal melanoma, selumetinib compared with chemotherapy r

207 Almost all uveal melanomas showing chromosome 3 loss (i.e., monosom

208 To examine the all-cause mortality and uveal melanoma specific mortality among newly diagnosed

209 We report our experience with uveal melanoma-specific gene expression profile (GEP) te

210 edle aspiration biopsy for cytopathology and uveal melanoma-specific GEP testing for molecular progno

211 The 5-year uveal melanoma-specific survival probability was 82.9% (

212 OCM-1 human uveal melanoma spheroids were implanted in six nude rats

213 C918 human uveal melanoma spheroids were implanted in the choroids

214 Although an accurate uveal melanoma staging system is needed to improve resea

215 Among the characteristics of uveal melanoma that are associated with a poor prognosis

216 tereotactic radiotherapy in the treatment of uveal melanoma that cannot be handled with ruthenium-bra

217 Uveal melanoma that spreads to the liver can be categori

218 fin-embedded tissues (n = 47) from 124 large uveal melanomas that underwent primary treatment by enuc

219 Twenty-four consecutive patients with uveal melanomas that were near, touching, or surrounding

220 Of 7731 patients with posterior uveal melanoma, the AJCC classification based on T was c

221 Patient 1 had metastatic uveal melanoma; the findings resolved without interventi

222 and myeloid suppressor cell populations, in uveal melanoma there is evidence that IL-1 can inhibit p

223 BAP1 immunohistochemical staining of primary uveal melanoma to evaluate metastatic risk.

224 autopsy from patients who died of metastatic uveal melanoma to the liver.

225 g (GEP) assay that assigns primary posterior uveal melanomas to prognostic subgroups: class 1 (low me

226 e after I-125 brachytherapy in patients with uveal melanoma treated and followed in a Spanish referra

227 ospective chart review of 7872 patients with uveal melanoma treated at the Ocular Oncology Service, W

228 dy reviewing data from patients with primary uveal melanoma treated between October 2003 and October

229 nd histology slides of patients with primary uveal melanoma treated by enucleation were reviewed.

230 We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination.

231 Patients with uveal melanoma treated with plaque radiotherapy were div

232 onic lymphocytic leukemia, breast cancer and uveal melanoma tumor samples, we show that hundreds of c

233 ein kinase pathway that is activated in most uveal melanoma tumors.

234 Uveal melanoma (UM) can be divided into prognostically s

235 e of genetic risk factors in the etiology of uveal melanoma (UM) has been strongly suggested, the gen

236 expression profile (GEP) testing segregates uveal melanoma (UM) into 2 main prognostic classes.

237 Uveal melanoma (UM) is a genetically and biologically di

238 Human uveal melanoma (UM) is a major ocular malignant tumor wi

239 Uveal melanoma (UM) is a rare intraocular tumor that, si

240 Uveal melanoma (UM) is the most common cancer in adult e

241 Uveal melanoma (UM) is the most common primary intraocul

242 Uveal melanoma (UM) is unique among cancers in displayin

243 istopathologic growth patterns of metastatic uveal melanoma (UM) to the liver.

244 Uveal melanoma (UM) was a fatal malignancy in 40% to 50%

245 eration (SCD) has been observed in eyes with uveal melanoma (UM), but, to our knowledge, a definitive

246 ring the human eIF1A NTT are associated with uveal melanoma (UM).

247 e been described in the following 5 genes in uveal melanoma (UM): BAP1, EIF1AX, GNA11, GNAQ, and SF3B

248 Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinc

249 tions in GNAQ or GNA11 occurs in over 80% of uveal melanomas (UMs) and activates MAPK.

250 is associated with more benign behavior for uveal melanomas (UMs) with an otherwise high risk of met

251 BRAF mutations are rare in uveal melanomas (UMs), but somatic mutations in the G pr

252 ogenes and tumor suppressor genes in primary uveal melanomas using a high-throughput profiling system

253 sc-Met levels in patients with nonmetastatic uveal melanoma vs patients with metastatic uveal melanom

254 Metastasis of uveal melanoma was 2.8 times higher in patients with iri

255 quencing from blood samples of patients with uveal melanoma was correlated with clinical characterist

256 cleral necrosis after plaque radiotherapy of uveal melanoma was detected in 1% of cases.

257 nts aged 45 to 79 years with newly diagnosed uveal melanoma was recruited between 2002 and 2004 from

258 , mammary carcinoma, cutaneous melanoma, and uveal melanoma), we demonstrate that transfection of hum

259 The cytologic characteristics of uveal melanoma were analyzed for 150 consecutive patient

260 Main prognostic factors for the death of uveal melanoma were ciliary body involvement (HR: 1.7 (9

261 l of 21 consecutive patients with metastatic uveal melanoma were enrolled between June 7, 2013, and S

262 A total of 459 patients with posterior uveal melanoma were enrolled from 12 independent centers

263 y, patients with melanocytosis who developed uveal melanoma were found to have double the risk for me

264 None of the mutations associated with uveal melanoma were found.

265 ients who underwent plaque brachytherapy for uveal melanoma were included.

266 tant Galpha11 proteins causing FHH2, ADH2 or uveal melanoma were transfected in CaSR-expressing HEK29

267 Seventy-eight patients with uveal melanoma were treated.

268 Indications for secondary enucleations for uveal melanoma were tumor recurrence, neovascular glauco

269 ntroduce the first transgenic mouse model of uveal melanoma, which develops cancers induced by expres

270 ariants in consecutive Finnish patients with uveal melanoma who come from a high-risk region for the

271 logy referral center among 507 patients with uveal melanoma who consented for collection of blood sam

272 Retrospective case series of 6 patients with uveal melanoma who had developed cutaneous vitiligo and

273 Twenty-five patients with stage IV uveal melanoma who had received 0-1 prior systemic thera

274 ic variants of BAP1 in Finnish patients with uveal melanoma who live in a high-risk region for this c

275 survival in high-risk patients with primary uveal melanoma who received adjuvant sunitinib with inst

276 ce of 96 patients with clinical diagnosis of uveal melanoma who underwent prognostication at the time

277 Patients with uveal melanoma who underwent transscleral or transvitrea

278 cutive patients with a clinical diagnosis of uveal melanoma who were treated at the Cleveland Clinic

279 metastasis differs in patients with primary uveal melanoma with different grades of nuclear BAP1 imm

280 sion was found to be a peripapillary primary uveal melanoma with distinct non-pigmented and pigmented

281 Five patients had uveal melanoma with extrascleral extension, 2 patients h

282 al was significantly longer in patients with uveal melanoma with high nuclear BAP1 stain (P = 0.004).

283 in patients treated with proton therapy for uveal melanoma with ischemic retinal detachment prevente

284 Ninety-six patients affected by posterior uveal melanoma with large exudative retinal detachment (

285 s: Ninety-six patients affected by posterior uveal melanoma with large exudative retinal detachment (

286 disomy 3 uveal melanoma; and iv) monosomy 3 uveal melanoma with long-term survival.

287 ned subgroups of uveal melanoma: i) disomy 3 uveal melanoma with long-term survival; ii) metastasizin

288 Large series of FNAB for uveal melanoma with no extraocular recurrence have been

289 sforming our understanding and management of uveal melanoma with the ultimate goal of improving patie

290 nal experience with plaque brachytherapy for uveal melanomas with a focus on local control rates, fac

291 iogenesis was present in the ciliary body in uveal melanomas with and without extraocular extension,

292 Uveal melanomas with BAP1 mutations demonstrate sensitiv

293 g splicing factor 3B subunit 1, in low-grade uveal melanomas with good prognosis.

294 iency (SCID) mouse xenograft models of human uveal melanoma, with the goal of modeling tumor growth t

295 As controls, 174 patients with uveal melanoma without metastasis were included.

296 iated protein-1 (BAP1) expression of primary uveal melanomas without and with metastasis, and to anal

297 nes and the blood serum samples of mice with uveal melanoma xenografts contained significant levels o

298 Uveal melanoma xenografts growing in the liver in vivo a

299 d in the blood serum samples of 24 mice with uveal melanoma xenografts, 57 patients with uveal melano

300 c uveal melanoma vs patients with metastatic uveal melanoma yielded an area under the curve of 0.82 (